MARÍA PILAR
GARCÍA ALFONSO
Profesora asociada de Ciencias de la Salud
Hospital Universitario Reina Sofia
Córdoba, EspañaPublications in collaboration with researchers from Hospital Universitario Reina Sofia (24)
2024
-
Delphi consensus for the third-line treatment of metastatic colorectal cancer
Clinical and Translational Oncology
-
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
Clinical and Translational Oncology
-
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study
Clinical and Translational Oncology
2023
-
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
Biomedicine and Pharmacotherapy, Vol. 159
-
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials
Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230
-
Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3378-3394
-
SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2718-2731
2022
-
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
European Journal of Cancer, Vol. 177, pp. 154-163
-
Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer
Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210
-
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880
2021
-
Biomarkers associated with regorafenib first-line treatment benefits in metastatic colorectal cancer patients: Reframe molecular study
Cancers, Vol. 13, Núm. 7
-
Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study
Cancers, Vol. 13, Núm. 18
-
Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept
Clinical and Translational Oncology, Vol. 23, Núm. 8, pp. 1520-1528
-
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial
European Journal of Cancer, Vol. 145, pp. 158-167
-
Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer
Clinical Colorectal Cancer, Vol. 20, Núm. 4, pp. 305-313
2019
-
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: A pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
BMC Cancer, Vol. 19, Núm. 1
-
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: The ULTRA trial
Annals of Oncology, Vol. 30, Núm. 5, pp. 796-803
-
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials
ESMO Open, Vol. 4, Núm. 6
2018
-
A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer
Clinical Colorectal Cancer, Vol. 17, Núm. 2, pp. e323-e329
2011
-
Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico
Revista Espanola de Patologia, Vol. 44, Núm. 1, pp. 32-48